A market forecast from IndexBox projects the global vegan collagen peptides market growing at a compound annual rate of about 8.5% between 2026 and 2035, reaching a market index of roughly 225 by 2035 against a 2025 baseline of 100. The report frames the category as moving from niche specialty ingredient to mainstream functional wellness product.

"Vegan collagen peptides" is a commercial label rather than a chemical one: animal collagen is not plant-derived, so these products rely on fermentation and bioengineering to produce peptide inputs. IndexBox calls scalable fermentation capacity a critical bottleneck for the category, which is a notable thing to say about an ingredient already sitting on mainstream grocery shelves.

Where the demand is

Beauty and skin health is the largest application, driven by what the report calls the beauty-from-within trend and ingestible products positioned around skin elasticity, hydration and anti-aging. Joint and bone health is the second pillar, with brands blending vegan collagen peptides alongside turmeric, boswellia and MSM as plant-based alternatives to glucosamine and chondroitin.

Sports nutrition and general wellness fill out the rest, and a small "other" segment covers pet supplements and fortified foods. Representative participants named across segments include Vital Proteins, Garden of Life, Ancient Nutrition, Sunwarrior and Codeage.

The clinical validation gap

Here is the interesting tension. IndexBox repeatedly identifies clinical validation and proprietary blends as the differentiators that will command price premiums through 2035, and notes that joint health growth may be tempered by the need for robust clinical evidence. It does not cite a single trial, outcome figure or published study anywhere in the forecast.

That is normal for a category study, which is measuring commerce rather than biology. But it means the premium tier of this market is being forecast on the promise of evidence that the report itself does not point to.

Margins and regions

The category is splitting in two, according to the report: a commoditizing mass segment where retailer private label applies margin pressure, and a premium benefit-led tier sold direct to consumers. North America remains the largest market, Asia-Pacific the fastest growing.

IndexBox also flags that rules on structure and function claims vary significantly by region, creating both opportunity and risk. Its baseline assumes that regulatory environment stays stable.

Bottom line

The growth case rests on clean-label preference, ethical sourcing and an aging population, none of which require a trial result to hold. Whether the premium end holds its pricing is the open question, and the report's own framing says that depends on evidence it does not show.